| The Medicines Company's Full Analysis of CHAMPION Phase III... |
|
The Medicines Company (NASDAQ: MDCO) today announced the data from 13,941 patients treated in the discontinued CHAMPION Phase III program of cangrelor. While cangrelor did... More »
|
|
Genetic Engineering News - Nov. 15, 2009
|
| American Heart Association Late-Breaking Clinical Trial... |
|
- A new reversible, intravenous blood thinner did not show superiority over an irreversible one currently approved for use. - Further investigation of the new anti-clotting... More »
|
|
Genetic Engineering News - Nov. 15, 2009
|
| The Medicines Company's Full Analysis of CHAMPION Phase III... |
|
The Medicines Company (NASDAQ: MDCO) today announced the data from 13,941 patients treated in the discontinued CHAMPION Phase III program of cangrelor. While cangrelor did... More »
|
|
Genetic Engineering News - Nov. 15, 2009
|
| American Heart Association Late-Breaking Clinical Trial... |
|
Study highlights: - A new reversible, intravenous blood thinner did not show superiority over an irreversible one currently approved for use. - Further investigation of the... More »
|
|
Genetic Engineering News - Nov. 15, 2009
|
| AHA: IV Antiplatelet Drug No CHAMPION |
|
ORLANDO -- The novel fast-on, fast-off intravenous antiplatelet agent cangrelor given at the time of percutaneous coronary intervention or stenting did not reduce the rate of... More »
|
|
MedPage Today - Nov. 15, 2009
|
| American Heart Association Late-Breaking Clinical Trial... |
|
Study highlights: - A new reversible, intravenous blood thinner did not show superiority over an irreversible one currently approved for use. - Further investigation of the... More »
|
|
Globe Investor - Nov. 15, 2009
|
| American Heart Association Late-Breaking Clinical Trial... |
|
Study highlights: - A new reversible, intravenous blood thinner did not show superiority over an irreversible one currently approved for use. - Further investigation of the... More »
|
|
Houston Chronicle - Nov. 15, 2009
|
| The Medicines Company's Full Analysis of CHAMPION Phase III... |
|
Data From Two International Trials With Nearly 14,000 Patients Presented at American Heart Association Scientific Sessions and Published in Two Papers in the New England... More »
|
|
Sys-Con Media - Nov. 15, 2009
|
| The Medicines Company's Full Analysis of CHAMPION Phase III... |
|
The Medicines Company (NASDAQ: MDCO) today announced the data from 13,941 patients treated in the discontinued CHAMPION Phase III program of cangrelor. While cangrelor did... More »
|
|
Interest!ALERT - Nov. 15, 2009
|
| American Heart Association Late-Breaking Clinical Trial... |
|
Study highlights: - A new reversible, intravenous blood thinner did not show superiority over an irreversible one currently approved for use. - Further investigation of the... More »
|
|
Red Orbit - Nov. 15, 2009
|